【导读】晚期小细胞肺癌（SCLC）的一线治疗仍有改进的空间。9月27日，中山大学方文峰教授研究团队在期刊《Signal Transduction and Targeted Therapy》上发表了研究论文，题为“Surufatinib plus ...

He was treated with four cycles of etoposide and cisplatin chemotherapy, but his hCG level had not returned to normal at the end of the treatment. Postchemotherapy CT showed no evidence of ...

CO: Cyclophosphamide and vincristine; EMA: Etoposide, methotrexate and actinomycin D; iv.: Intravenous. 1 Paclitaxel 135 mg/m 2 by iv. infusion over 3 h Cisplatin 60 mg/m 2 iv. infusion over 3 h ...

The MTD for the concomitant-boost technique, when combined with cisplatin/etoposide chemotherapy, has been determined at 61.2 Gy. [17] Thus, there are 3 plausible treatment regimens for delivering ...

We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...

Researchers divided the women into three groups depending on the severity of their cancer and treated them with an intensive regime of cisplatin and another drug called etoposide. The response ...

We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...

Round dose to nearest 50mg increment. Range: 70mg/m 2 per day for 4 days to 100mg/m 2 per day for 5 days. Repeat course every 3 to 4 weeks after recovery (esp myelosuppression). Renal impairment ...

He was seen by medical oncology and radiation oncology, given a diagnosis of limited-stage SCLC, and recommended treatment with cisplatin and etoposide concurrent with once-daily radiotherapy. SCLC is ...

(TopAlliance Biosciences), announce that the European Commission (EC) has approved toripalimab (European trade name: LOQTORZI ...

A randomised phase III trial comparing conventional dose chemotherapy using Paclitaxel, Ifosfamide and Cisplatin (TIP) with high dose chemotherapy using mobilising Paclitaxel plus Ifosfamide followed ...